人工血管市場 - 予測（2021年～2026年）
Vascular Graft Market - Forecasts from 2021 to 2026
|人工血管市場 - 予測（2021年～2026年）|
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 118 Pages
The global vascular graft market is projected to grow at a CAGR of 5.04% to reach US$7.955 billion by 2026, from US$5.637 billion in 2019
A vascular graft is a surgical technique that reconnects blood arteries to shift blood flow from one part of the body to another. The most common reason for vascular grafting is to increase blood flow to an organ fed by a damaged artery by bypassing a total or partial obstruction. These grafts range in size from 5-8 mm in diameter. This allows the body's blood flow to return to normal. Catheter-based devices are inserted through a small incision and guided with the use of real-time imaging technology in vascular transplant surgeries. Development of efficient and advanced novel products using tissue-engineered and biological materials, increased public awareness of peripheral artery diseases and coronary diseases, increased government initiatives around the world propel the global vascular graft market during the forecast period. The major growth drivers of the vascular graft market are the growing incidence of cardiovascular illnesses such as hypertension, coronary artery disease, and cardiac aneurysms, as well as the rising prevalence of diabetes. Moreover, increased vascular graft usage in emerging nations such as China, India, and others would open up new potential for the vascular graft market.
The vascular graft market growth is anticipated to be further aided by the rise in the senior population, technological improvements, and changes in lifestyle (consumption of junk food, cigarettes, and alcohol). The growing prevalence of end-stage renal diseases (ESRD) has further boosted the demand for vascular grafting during the forecast period. Dialysis, which is often used by individuals with ESRD, is the sole option for kidney transplantation. Three times a week, hemodialysis is performed. Many patients' superficial veins have been depleted as a result of continuous dialysis, and vascular grafts are the only way to continue hemodialysis. In 2017, 124,500 new cases of ESRD were reported in the United States, with a crude (uncorrected) incidence rate of 370.2 per million per year. The number of people living with ESRD is increasing at a rate of around 20,000 each year.
Due to strong medical reimbursement facilities and technical advancements, North America has anticipated led the vascular graft industry. Due to a rapidly growing geriatric population, increased consumer awareness, increased healthcare expenditure, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing countries such as China and India in this region, Asia Pacific is expected to grow at the fastest rate. The increased incidence of CKD, healthcare reforms, government efforts and investments, and rapid growth in the elderly population are all contributing to the Asia Pacific market's expanding growth. In addition, emerging markets such as Australia, Singapore, Japan provide various development possibilities for vascular grafts market participants because of an aging population and an increase in end-stage renal disease.
One of the major reasons for the growth of the global vascular graft market is the growing demand for hemodialysis. The growing need for hemodialysis products will boost demand for vascular grafts and propel the sector forward. Dialysis operations will become more common as the number of people with end-stage renal illness rises, as will the number of people with chronic kidney disease. Hemodialysis patients also require a well-functioning arteriovenous graft for a successful hemodialysis operation. According to research from the National Renal Foundation, 785,883 Americans suffered kidney failure in 2018 and required dialysis or a kidney transplant to live. As a result, the rising prevalence of chronic renal disease will lead to an increase in the number of hemodialysis procedures. Cook Medical's Zenith fenestrated endovascular graft earned FDA breakthrough device designation in March 2021. For life-threatening or profoundly disabling diseases or conditions, the product delivers more effective therapy or diagnosis. This strategy is anticipated to add value to the company's current portfolio while also generating money through sales. Furthermore, the increasing prevalence of cardiovascular illnesses throughout the world will drive up demand for vascular grafts.
A major restraint in the growth of the global vascular graft market is the product recalls and failures limiting the adoption of vascular graft during the forecast period. Patients might suffer serious or even fatal consequences as a result of product failures. Several businesses' goods have been recalled from the market throughout the years owing to product faults or other concerns. End-user perceptions of graft safety may be harmed as a result of market trends, which may influence their acceptance in treatment processes. As a result, the adoption of vascular grafts has been restrained during the forecast period.
The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. Production activities are interrupted because of lockdown measures enforced in numerous countries. The COVID-19 impact on the global vascular graft market has been adverse owing to the production halt by industries due to the temporary lockdown implemented by several governments to break the cycle of the virus. The disruption in the demand and supply chain has further hampered the market in the forecast period. Despite the availability of OPD administrations at emergency clinics, the number of patient visits to clinics has fallen significantly in recent months. Despite this, patient visits to medical facilities have fallen significantly as a result of the lockdown in several countries. As a result, the number of suggestive tests has decreased. The sale of vascular grafts has also decreased as a result of this. Since the majority of vascular grafts and interventional techniques are elective, many of these procedures have been postponed. This is another issue that has a negative impact on the market for vascular grafts. However, in the post-COVID-19 scenario, the global vascular graft market is expected to boom with the increasing demand during the forecast period.
The market leaders for the pretreatment coating market are Hancock Jaffe Laboratories Inc., Getinge Group, W.L. Gore & Associates, Vascular Flow Technologies, C.R. Bard Inc., Artegraft Inc., Vascular Genesis, B. Braun Melsungen AG, LeMaitre Vascular Inc., and Terumo Aortic.